Pancreatic Cancer Research

ResearcherChinese Academy of SciencesActive in the last 2 years

Michael Bouvet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0086-2159; OpenAlex author ID A5009960666, A5087572625; NIH RePORTER profile ID 2086061. Sources: OpenAlex.

Their work

Papers
81 (first author 3, last author 33)
Trials
0
Grants
3
Labs led
1
Collaborators
96
Papers, trials and grants by year

2011: 4 papers · 2012: 9 papers · 2013: 5 papers, 1 grant · 2014: 10 papers · 2015: 12 papers, 1 grant · 2016: 3 papers · 2017: 7 papers · 2018: 10 papers · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 4 papers · 2026: 1 paper, 1 grant

Papers 50 of 81

  1. Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells. Co-author DOI 10.21873/anticanres.18338↗
  2. Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells. Co-author DOI 10.21873/anticanres.17396↗
  3. Simultaneous Targeting of Multiple Hallmarks of Cancer With Recombinant Methioninase, Rapamycin and Chloroquine Is Specific and Synergistic to MiaPaCa-2 Pancre… Co-author DOI 10.21873/anticanres.17825↗
  4. Mucin4 (MUC4) Antibody Labeled with an NIR Dye Brightly Targets Pancreatic Cancer Liver Metastases and Peritoneal Carcinomatosis. Last author DOI 10.3390/cancers17122031↗
  5. Brightly Visualizing Pancreatic Cancer Margins in Orthotopic Mouse Models with an Anti-CA19-9 Antibody Conjugated to a Near-Infrared Fluorophore. Last author DOI 10.3390/cancers17162617↗
  6. Extensive DNA Damage and Loss of Cell Viability Occur Synergistically With the Combination of Recombinant Methioninase and Paclitaxel on Pancreatic Cancer Cell… Co-author DOI 10.21873/cgp.20475↗
  7. Targeting Human Pancreatic Cancer with a Fluorophore-Conjugated Mucin 4 (MUC4) Antibody: Initial Characterization in Orthotopic Cell Line Mouse Models. Last author DOI 10.3390/jcm13206211↗
  8. Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216150↗
  9. Proof of Principle of Combining Fluorescence-Guided Surgery with Photoimmunotherapy to Improve the Outcome of Pancreatic Cancer Therapy in an Orthotopic Mouse … Last author DOI 10.1245/s10434-022-12466-4↗
  10. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Co-author DOI 10.3390/cancers15030652↗
  11. Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study. Last author DOI 10.3390/jpm13050857↗
  12. High Incidence of Lymph-node Metastasis in a Pancreatic-cancer Patient-derived Orthotopic Xenograft (PDOX) NOG-Mouse Model. Co-author DOI 10.21873/anticanres.15532↗
  13. Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft. Last author DOI 10.21873/invivo.12676↗
  14. Fluorescent Anti-CEA Nanobody for Rapid Tumor-Targeting and Imaging in Mouse Models of Pancreatic Cancer. Last author DOI 10.3390/biom12050711↗
  15. Establishment of PANDA - a new human pancreatic ductal adenocarcinoma cell line with 3D cell culture technology. Co-author DOI 10.4149/210924n1360↗
  16. Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model. Co-author DOI 10.1097/mpa.0000000000001709↗
  17. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.10.031↗
  18. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse… Co-author DOI 10.1016/j.canlet.2020.07.034↗
  19. Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer. Last author DOI 10.1016/j.surg.2020.02.020↗
  20. The future of tumour-specific fluorescence-guided surgery for pancreatic cancer. Last author DOI 10.1016/s2468-1253(20)30123-0↗
  21. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy. Co-author DOI 10.21873/anticanres.13726↗
  22. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Can… Co-author DOI 10.1002/jcb.26224↗
  23. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.06.016↗
  24. RT-PCR of peritoneal washings predicts peritoneal pancreatic cancer recurrence. Co-author DOI 10.1016/j.jss.2017.11.009↗
  25. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Co-author DOI 10.1016/j.tice.2018.05.003↗
  26. The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic. Last author DOI 10.1080/14737140.2018.1477593↗
  27. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived… Co-author DOI 10.1080/15384101.2018.1445907↗
  28. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopi… Co-author DOI 10.1080/15384101.2018.1480223↗
  29. Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore. Last author DOI 10.1245/s10434-018-6344-6↗
  30. Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model. Last author DOI 10.18632/oncotarget.26484↗
  31. Fluorescence-guided Surgery with Splenic Preservation Prevents Tumor Recurrence in an Orthotopic Nude-mouse Model of Human Pancreatic Cancer. Last author DOI 10.21873/anticanres.12270↗
  32. Improving theranostics in pancreatic cancer. First author DOI 10.1002/jso.24625↗
  33. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility co… Co-author DOI 10.1002/jso.24681↗
  34. Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer or… Co-author DOI 10.1080/15384101.2017.1315489↗
  35. eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth. Co-author DOI 10.1158/0008-5472.can-16-2594↗
  36. A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic canc… Co-author DOI 10.18632/oncotarget.11809↗
  37. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). Co-author DOI 10.18632/oncotarget.17667↗
  38. Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model. Last author DOI 10.18632/oncotarget.21331↗
  39. Imaging the microenvironment of pancreatic cancer patient-derived orthotopic xenografts (PDOX) growing in transgenic nude mice expressing GFP, RFP, or CFP. First author DOI 10.1016/j.canlet.2015.12.021↗
  40. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/2159-8290.cd-15-1346↗
  41. Targeting the insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging of human pancreatic cancer in orthotopic mouse model… Last author DOI 10.18632/oncotarget.7576↗
  42. Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer. Co-author DOI 10.1002/jso.23816↗
  43. Photoimmunotherapy lowers recurrence after pancreatic cancer surgery in orthotopic nude mouse models. Last author DOI 10.1016/j.jss.2015.02.037↗
  44. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) model r… Last author DOI 10.1016/j.pan.2015.02.008↗
  45. Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-… Co-author DOI 10.1038/cgt.2015.26↗
  46. Ratiometric activatable cell-penetrating peptides label pancreatic cancer, enabling fluorescence-guided surgery, which reduces metastases and recurrence in ort… Last author DOI 10.1245/s10434-014-4144-1↗
  47. Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. Last author DOI 10.1245/s10434-015-4553-9↗
  48. Near infra-red photoimmunotherapy with anti-CEA-IR700 results in extensive tumor lysis and a significant decrease in tumor burden in orthotopic mouse models of… Last author DOI 10.1371/journal.pone.0121989↗
  49. MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models. Last author DOI 10.1371/journal.pone.0122100↗
  50. Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer. First author DOI 10.1517/14656566.2015.1016912↗

Grants 3

  1. Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer R01CA256973↗
  2. Fluorophore-Conjugated Antibodies for Imaging and Resection of GI Tumors R01CA142669↗
  3. Color-Coded Imaging of Pancreatic Cancer Microenvironment for Drug Discovery R01CA132971↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert M. Hoffman · 73 shared papers, 2011–2026 · strength 6.12
  2. Surinder K. Batra · 6 shared papers, 1 shared grant, 2022–2026 · strength 2.37
  3. Thinzar Min Lwin · 14 shared papers, 2017–2025 · strength 1.77
  4. Yukihiko Hiroshima · 22 shared papers, 2013–2020 · strength 1.08
  5. Aaron M. Mohs · 5 shared papers, 2023–2025 · strength 0.97
  6. Kentaro Miyake · 12 shared papers, 2017–2022 · strength 0.96
  7. Kavita B. Mallya · 5 shared papers, 2022–2025 · strength 0.93
  8. Hiroto Nishino · 6 shared papers, 2020–2023 · strength 0.88
  9. Takashi Murakami · 14 shared papers, 2014–2018 · strength 0.82
  10. Itaru Endo · 15 shared papers, 2013–2020 · strength 0.80
  11. Kei Kawaguchi · 8 shared papers, 2017–2022 · strength 0.71
  12. Michiaki Unno · 8 shared papers, 2017–2022 · strength 0.71
  13. Ali A. Maawy · 16 shared papers, 2013–2017 · strength 0.70
  14. Michael A. Turner · 4 shared papers, 2022–2023 · strength 0.67
  15. Shinji Miwa · 9 shared papers, 2013–2025 · strength 0.64
  16. Sunidhi Jaiswal · 3 shared papers, 2024–2025 · strength 0.62
  17. Maneesh Jain · 3 shared papers, 2024–2025 · strength 0.62
  18. Kristin E. Cox · 3 shared papers, 2023–2025 · strength 0.55
  19. Norihiko Sugisawa · 4 shared papers, 2019–2022 · strength 0.46
  20. Ho Kyoung Hwang · 6 shared papers, 2017–2018 · strength 0.42
  21. Sei Morinaga · 2 shared papers, 2024–2025 · strength 0.40
  22. Cristina Angela Metildi · 10 shared papers, 2011–2015 · strength 0.39
  23. Yasushi Ichikawa · 7 shared papers, 2014–2020 · strength 0.37
  24. Meng Yang · 2 shared grants, 2013–2015 · strength 0.36
  25. Jinsoo Kim · 1 shared paper, 2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.